** Shares of drugmaker Eli Lilly rise 10.2% to $810.13 premarket
** Co says its oral drug orforglipron led to an average weight loss of 7.9% and lowered blood sugar for overweight patients with type 2 diabetes in a late-stage trial
** U.S.-listed shares of Lilly's obesity rival Novo Nordisk NOVOb.CO down 3.8%
** Up to last close, LLY down 4.8% YTD
(Reporting by Christy Santhosh in Bengaluru)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。